BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
3239 results:

  • 1. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
    Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
    Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
    [No Abstract]    [Full Text] [Related]  

  • 2. Trastuzumab deruxtecan in previously treated her2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.
    Petit T; Hajjaji N; Antoine EC; Benderra MA; Gozy M; Foa C; Mouysset JL; Grenier J; Mousseau M; Mailliez A; Saghatchian M; Lachaier E; Desmoulins I; Hennequin A; Maes P; Loirat D; Ricci F; Diéras V; Berton D; Tiong FL; Teixeira L; Dohollou N; Lévy C; Bachelot T; Pierga JY
    Cancer Med; 2024 May; 13(9):e7168. PubMed ID: 38733172
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. KRAS Allelic Variants in Biliary Tract cancers.
    Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
    JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)].
    Trastuzumab Deruxtecan Clinical Management Pathway and Adverse Reaction Management Consensus Expert Group
    Zhonghua Zhong Liu Za Zhi; 2024 Apr; 46(4):304-318. PubMed ID: 38644266
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach.
    Alsaiari AA; Gharib AF; Bakhuraysah MM; Alrehaili AA; Algethami SM; Alsaif HA; Al Harthi N; Hakami MA
    Med Oncol; 2024 Apr; 41(5):117. PubMed ID: 38630325
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker lung Adenocarcinoma Patients without EGFR or ALK Alterations.
    Park SJ; Ju S; Goh SH; Yoon BH; Park JL; Kim JH; Lee S; Lee SJ; Kwon Y; Lee W; Park KC; Lee GK; Park SY; Kim S; Kim SY; Han JY; Lee C
    Cancer Res; 2024 May; 84(9):1491-1503. PubMed ID: 38607364
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Promoting the Anticancer Activity with Multidentate Furan-2-Carboxamide Functionalized Aroyl Thiourea Chelation in Binuclear Half-Sandwich Ruthenium(II) Complexes.
    Thangavel SK; Mohamed Kasim MS; Rengan R
    Inorg Chem; 2024 Apr; 63(16):7520-7539. PubMed ID: 38590210
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Establishment of a Novel cancer-Specific Anti-her2 Monoclonal Antibody H
    Kaneko MK; Suzuki H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Universal CAR T cells targeted to her2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.
    Nagy L; Mezősi-Csaplár M; Rebenku I; Vereb G; Szöőr Á
    Front Immunol; 2024; 15():1365172. PubMed ID: 38562932
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
    Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
    Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Outcomes of the patients with metastatic male breast cancer.
    Dogan I; Khanmammadov N; Ozkurt S; Aydiner A; Saip P
    J Cancer Res Ther; 2024 Jan; 20(1):98-102. PubMed ID: 38554305
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-lung01): primary results of the her2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Cardiac troponin I as predictor for cardiac and other mortality in the German randomized lung cancer screening trial (LUSI).
    Cortés-Ibáñez FO; Johnson T; Mascalchi M; Katzke V; Delorme S; Kaaks R
    Sci Rep; 2024 Mar; 14(1):7197. PubMed ID: 38531926
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Discovery of Novel 5,6-Dihydro-4
    Yang L; Li Y; Du Y; Guo Y; Guo Z; Liu B; Liu J; Liu Y; Niu H; Sun Y; Yan H; Yang Y; Yu S; Zhang Y; Zhang Y; Zheng K; Zheng N; Zhang X; Zhang Q; Hu L
    J Med Chem; 2024 Apr; 67(7):5662-5682. PubMed ID: 38518121
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Targeted dual degradation of her2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in her2-positive breast cancer models.
    Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
    Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
    Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
    Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 162.